Show simple item record

dc.contributor.editorSong, Im-Sook
dc.date.accessioned2022-01-11T13:51:18Z
dc.date.available2022-01-11T13:51:18Z
dc.date.issued2021
dc.identifierONIX_20220111_9783036524610_903
dc.identifier.urihttps://directory.doabooks.org/handle/20.500.12854/77071
dc.description.abstractThis Book serves to highlight the mechanisms related to the low intestinal drug absorption, the strategies to overcome the obstacles or intestinal drug absorption, and in situ, in vitro, and in silico methodologies to predict to intestinal drug absorption. This Book presents a series of drug absorption studies and related technologies that predict intestinal permeation of drugs that govern the pharmacokinetic features of therapeutic drugs. It also contains the mechanistic understanding regarding the first-pass metabolism and intestinal efflux that modulate the pharmacokinetics of drug and suggest the formulation strategies to enhance the bioavailability of investigated drugs.
dc.languageEnglish
dc.subject.classificationthema EDItEUR::M Medicine and Nursingen_US
dc.subject.classificationthema EDItEUR::K Economics, Finance, Business and Management::KN Industry and industrial studies::KND Manufacturing industriesen_US
dc.subject.otherrebamipide
dc.subject.othernanocrystals
dc.subject.otheroral mucositis
dc.subject.otherhydrogel
dc.subject.otherendocytosis
dc.subject.otherenoxaparin
dc.subject.otherlipid–polymer hybrid nanoparticles
dc.subject.otheroral
dc.subject.otherintestinal absorption
dc.subject.othernaftidrofuryl oxalate
dc.subject.othersolubility
dc.subject.otherpermeability
dc.subject.otherdissolution profiles
dc.subject.otherpharmaceutical availability
dc.subject.otherBCS drug classification
dc.subject.othernon-sink condition
dc.subject.othersolubility–permeability interplay
dc.subject.otherunstirred water layer
dc.subject.otherpoorly soluble drugs
dc.subject.othersolubilizer additive
dc.subject.otherphenylketonuria
dc.subject.otherl-phenylalanine ammonia-lyase
dc.subject.otherenzyme
dc.subject.otherkinetics
dc.subject.othercatabolism disorder
dc.subject.otherbiomedical drug
dc.subject.otherP-glycoprotein
dc.subject.otherbreast cancer resistance protein
dc.subject.otherLY335979
dc.subject.otherWK-X-34
dc.subject.otherin vivo–in vitro correlation
dc.subject.otherlipolysis-permeation
dc.subject.otherlipid-based drug delivery system
dc.subject.otherPermeaPad
dc.subject.othercinnarizine
dc.subject.otherlipolysis
dc.subject.otheramorphous solid dispersion
dc.subject.othercandesartan Cilexetil
dc.subject.otherPVPK30
dc.subject.otherpH-modulation
dc.subject.otherspray drying
dc.subject.otherbioavailability
dc.subject.othernasal administration
dc.subject.otherspray-drying
dc.subject.otherchitosan
dc.subject.othermicrosphere
dc.subject.othermeloxicam
dc.subject.othersilymarin
dc.subject.otherD-α-Tocopherol polyethylene glycol 1000 succinate (TPGS)
dc.subject.otherliver distribution
dc.subject.otheracetaminophen-induced hepatotoxicity
dc.subject.otherextra virgin olive oil
dc.subject.othersecoiridoids
dc.subject.othermetabolism
dc.subject.otherphenolic compounds
dc.subject.otherintestinal permeability
dc.subject.otherdrug-phytochemical interaction
dc.subject.otherhepatic metabolism
dc.subject.othermixed inhibition
dc.subject.otherquercetin
dc.subject.otherrepaglinide
dc.titleDrug Absorption Studies: In Situ, In Vitro and In Silico Models
dc.typebook
oapen.identifier.doi10.3390/books978-3-0365-2460-3
oapen.relation.isPublishedBy46cabcaa-dd94-4bfe-87b4-55023c1b36d0
oapen.relation.isbn9783036524610
oapen.relation.isbn9783036524603
oapen.pages171
oapen.place.publicationBasel, Switzerland


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0/